Introduction {#s1}
============

The lymphatic system is important for fluid and protein homeostasis, lipid transport, and immunity. Lymphatic malfunction is linked to many pathologies including lymphedema, cancer metastasis, and cardiovascular disease ([@bib45]; [@bib56]; [@bib2]; [@bib49]; [@bib35]). Primitive lymphatic vessels are derived from lymphatic endothelial cell (LEC) progenitors that transdifferentiate from venous blood endothelial cells (BECs) and subsequently migrate away from the veins to form lymphatic vessels ([@bib46]; [@bib18]; [@bib27]; [@bib39]). A variety of factors have been identified that are required for proper regulation of lymphangiogenesis during development and disease, including PROX1, SOX18, COUPTFII, VEGFC/VEGFR3, NRP2, CCBE1, CLEC2, YAP/TAZ, and NFATC1 ([@bib59]; [@bib9]; [@bib24]; [@bib15]; [@bib48]; [@bib61]; [@bib54]; [@bib17]; [@bib32]; [@bib51]; [@bib4]; [@bib7]). Some of our current knowledge regarding development of the lymphatic system has come from research using the zebrafish, a superb model for studying vertebrate organogenesis with optically clear, externally developing embryos ideal for high-resolution live imaging. The development of the zebrafish lymphatic vascular system is highly conserved and stereotyped ([@bib60]; [@bib43]; [@bib23]; [@bib31]), and the availability of transgenic zebrafish expressing fluorescent reporters in lymphatic endothelium makes it straightforward to monitor lymphatic development at the single cell level in vivo and visualize even subtle lymphatic defects using optimized high-resolution microscopy technologies ([@bib22]).

MicroRNAs are important posttranscriptional regulators that play crucial roles in developmental, physiological, and disease-related processes in animals ([@bib16]). They are noncoding RNAs approximately 22 nucleotide long that guide Argonaute proteins for gene silencing by mRNA degradation and/or translational repression ([@bib20]). Targeting of microRNAs is accomplished by binding of the key nucleotides 2--8 (the 'seed' sequence) and additional microRNA sequences to complementary sequences in target mRNAs ([@bib3]). The majority of microRNA target sites are located in the 3' untranslated regions (UTRs) of mRNAs, although some microRNA targeting also occurs in 5'UTR and coding sequences ([@bib52]; [@bib36]; [@bib21]). MicroRNA regulatory networks are thought to confer robustness to biological processes by reinforcing transcription programs and attenuating aberrant transcripts by either switching off or fine-tuning gene expression, helping to buffer against random fluctuations in transcript copy number ([@bib11]; [@bib50]; [@bib8]). Although we know a great deal about the roles of protein-coding genes during lymphangiogenesis, we still have limited insight into how post-transcriptional mechanisms regulate lymphatic development. Profiling of microRNAs in human lymphatic endothelial cells (LECs) and blood endothelial cells (BECs) has identified BEC-specific microRNAs such as miR-31 and miR-181a that target Prox1 and prevent lymphatic specification in BECs ([@bib34]; [@bib25]; [@bib10]). These studies suggest some microRNAs can help BECs retain their identity by negatively regulating lymphatic development. Manipulation of endothelial microRNAs has also been shown to result in defective lymphatic development ([@bib28]; [@bib41]; [@bib6]). Although these studies have begun to shed light on the role of microRNAs during lymphangiogenesis, our understanding of the role lymphatic microRNAs play during lymphatic vessel development is still limited.

Here, we characterize miR-204, a highly conserved lymphatic-enriched microRNA isolated via small RNA sequencing of human endothelial cells, and demonstrate its critical function during lymphangiogenesis in vivo using the zebrafish. MicroRNA-204-deficient zebrafish display severe defects in lymphatic vessel formation, while excess mir-204 expression in endothelium drives precocious lymphangiogenesis. We identify NFATC1 as a conserved miR-204 target in both human lymphatic endothelial cells and in the zebrafish, with loss of miR-204-mediated silencing resulting in increased NFATC1 transcript levels. As in mammalian lymphatics, attenuating nfatc1 in the zebrafish promotes abnormal lymphatic expansion, and suppressing nfatc1 rescues lymphatic development in mir-204-deficient zebrafish. Our results thus identify a miR-204/NFATC1 molecular pathway critical for lymphatic development.

Results {#s2}
=======

miR-204 is enriched in human and zebrafish lymphatic endothelial cells {#s2-1}
----------------------------------------------------------------------

We performed small RNA sequencing on human lymphatic endothelial cells (LEC) and human blood endothelial cells (BEC) to identify microRNAs enriched in LECs compared to BECs. We used triplicate samples of total RNA isolated from human dermal lymphatic microvascular endothelial cells (HMVEC-dLy, representing LEC) and human umbilical vein endothelial cells (HUVEC, representing BEC) for sequencing ([Figure 1a](#fig1){ref-type="fig"}). Prior to sequencing, we used TaqMan quantitative RT-PCR to verify that HMVEC-dLy and HUVEC are enriched for markers representing lymphatic or blood vessel identity, respectively. We tested the expression of lymphatic vascular markers PROX1, FLT4 (also known as VEGFR3), and PDPN, and blood vascular markers NR2F2 (also known as COUP-TFII), KDR (also known as VEGFR2), CDH5 (also known as VE-Cadherin), and EGFL7. HMVEC-dLy express higher levels of PROX1, FLT4, and PDPN, while HUVEC showed enrichment for NR2F2, KDR, CDH5, and EGFL7, showing that these cell types appropriately express genes representative of lymphatic or blood vessel identity ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). A total of \~10 million reads were collected for each RNAseq sample and the sequences were aligned using the miRbase v22 ([@bib30]). We excluded from further analysis any microRNAs that were represented by less than 10 reads in three or more of the six (two triplicate) sequenced samples, resulting in 445 annotated microRNAs. 98 of these microRNAs showed a significant difference between the LEC and BEC samples (p\<0.01, false discovery rate (FDR) \< 0.01). The normalized sequencing data have been submitted to the Gene Expression Omnibus repository with accession number GSE126679. From the 98 microRNAs we identified 30 that were highly enriched in LECs (fold change (FC) \>4) and 20 that were highly enriched in BECs (FC \>4) ([Figure 1a](#fig1){ref-type="fig"} and [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Among the 30 LEC-enriched microRNAs, miR-204--5 p was by far the most highly enriched in LEC, with 105-fold higher representation in the LEC sequences compared to BEC ([Figure 1b](#fig1){ref-type="fig"}). Using the TaqMan microRNA qPCR assay, we confirmed that miR-204--5 p is very highly enriched in LEC compared to BEC, in contrast to previously reported vascular microRNAs miR-126 and miR-31 that are more highly enriched in BEC ([Figure 1c](#fig1){ref-type="fig"}).

![Identification of lymphatic microRNAs enriched in human and zebrafish lymphatic endothelial cells.\
(**a**) Schematic diagram of the workflow for small RNA sequencing from lymphatic (HMVEC-dLy) and blood (HUVEC) endothelial cells and selection of microRNAs enriched in lymphatic endothelial cells. (**b**) Relative fold enrichment of the 22 most highly enriched microRNAs in LEC versus BEC small RNA sequence data (average of triplicate samples from each group). (**c**) Quantitative TaqMan RT-PCR measurement of the relative expression of three different microRNAs in HMVEC-dLy (LEC) and HUVEC (BEC). Levels of mir-204 are normalized to HUVEC (BEC) levels, while levels of mir-126 and mir-31 are normalized to HMVEC-dLy (LEC) levels. Three biological replicates were analyzed. (**d**) Confocal image of a five dpf *Tg(mrc1a:eGFP)^y251^, Tg(kdrl:mCherry)^y171^* double-transgenic larva (lateral view, rostral to the left). (**e**) Confocal images of lymphatic (GFP-positive), arterial (mCherry-positive), and venous (GFP and mCherry double-positive) endothelial cell pellets isolated from dissociated five dpf transgenic animals such as that in panel d by Fluorescence Activated Cell Sorting (FACS). (**f**) Quantitative TaqMan RT-PCR measurement of the relative expression of mature mir-204, mir-126, and mir-31 in FACS-sorted zebrafish endothelial cells. FACS-sorted cells from \~1000 5 dpf larvae were used and three technical replicates were analyzed. Levels of mir-204 are normalized to venous (GFP and mCherry double-positive) levels, while levels of mir-126 and mir-31 are normalized to lymphatic (GFP-positive) levels. All graphs are analyzed by t-test and the mean ± standard deviation (SD) is shown. \*, p\<0.05; \*\*, p\<0.01; \*\*\*\*, p\<0.0001.\
10.7554/eLife.46007.005Figure 1---source data 1.List of microRNAs from the small RNA sequencing data with numeric values comparing LEC vs. BEC.\
10.7554/eLife.46007.006Figure 1---source data 2.Numerical data for [Figure 1](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.](elife-46007-fig1){#fig1}

We used the zebrafish as an in vivo system to examine the role of mir-204 during lymphatic development, beginning by testing whether zebrafish mir-204 is also enriched in LEC. Zebrafish have a conserved, highly stereotyped developing lymphatic vascular network that is readily visualized using transgenic reporter lines ([@bib43]; [@bib23]) ([Figure 1---figure supplement 2a,b](#fig1s2){ref-type="fig"}). We used 5 day post-fertilization (dpf) *Tg(mrc1a:eGFP)^y251^, Tg(kdrl:mCherry)^y171^* double-transgenic larvae with EGFP-positive lymphatic EC, mCherry-positive arterial EC, and EGFP and mCherry double-positive venous EC ([Figure 1d](#fig1){ref-type="fig"}) to isolate each of these endothelial cell populations by fluorescence activated cell sorting (FACS). Transgenic larvae were dissociated into single cells and subjected to FACS sorting to obtain EGFP-sorted lymphatic cells, mCherry-sorted arterial cells, and double-sorted venous cells ([Figure 1e](#fig1){ref-type="fig"}). The EGFP-sorted lymphatic cells showed strong expression of lymphatic markers lyve1b and prox1a, while arterial and venous endothelial cells expressed relatively low levels of these transcripts ([Figure 1---figure supplement 2c](#fig1s2){ref-type="fig"}). In contrast, blood vascular markers kdrl and cdh5 were more abundant in mCherry-sorted arterial and double-sorted venous cells compared to EGFP-sorted lymphatic cells ([Figure 1---figure supplement 2d](#fig1s2){ref-type="fig"}). Using these sorted endothelial cell populations we were able to show that zebrafish mir-204 is highly enriched in EGFP-sorted lymphatic cells, while the blood endothelial microRNAs mir-126 and mir-31 are more enriched in mCherry-positive or double-positive BECs ([Figure 1f](#fig1){ref-type="fig"}). These data show that miR-204 is a highly conserved microRNA enriched in the lymphatic endothelium in both humans and zebrafish.

Developmental lymphangiogenesis is suppressed by miR-204 deficiency {#s2-2}
-------------------------------------------------------------------

Human miR-204 is located in the sixth intron of TRPM3 (Transient Receptor Potential Cation Channel Subfamily M Member 3), and the mature microRNA is 100% conserved amongst a variety of vertebrate species ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). The zebrafish genome contains three paralogues of mir-204 ([miRBase.org](http://www.mirbase.org)). As in the human genome, one mir-204 is found in intron 5 of the zebrafish *trpm3* gene (*mir-204--1*) ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). However, additional zebrafish mir-204 sequences are also found in intron 5 of *trpm1a* and in intron 4 of *trpm1b* (*mir-204--2* and *mir-204--3*, respectively; [Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}). The single human *TRPM1* gene contains a closely related paralogue microRNA, miR-211, in intron 6. Although each of the three copies of mir-204 in the zebrafish has unique precursor sequences, their mature mir-204 sequences are 100% identical ([Figure 2a](#fig2){ref-type="fig"}). To determine the function of mir-204 in lymphatic vessel formation during early development, we began by using morpholino (MO) antisense oligomers to target and block the function of endogenous mir-204 in zebrafish. Knocking down microRNA function using MOs is an excellent targeting strategy for microRNAs because unlike protein-coding genes the functional products of microRNA genes are RNAs ([@bib14]). Four different MOs were designed to use different strategies to block mir-204 function ([Figure 2a](#fig2){ref-type="fig"}). The pan-204 MO targets the mature mir-204 sequence and knocks down all mir-204s. Precursor hairpin structures must be properly cleaved by Dicer to permit maturation of functional microRNAs ([@bib44]; [@bib14]; [@bib26]). We designed specific MOs targeting the dicer-cleavage sites of *mir-204--1*, *mir-204--2*, and *mir-204--3*, respectively, to individually block the maturation of each of the three precursor mir-204 sequences ([Figure 2a](#fig2){ref-type="fig"}). Injection of 0.5 ng of pan-204 MO led to highly efficient suppression of mature mir-204 levels ([Figure 2b](#fig2){ref-type="fig"}). At the 0.5 ng dose there were no noticeable morphological anomalies, although slightly higher doses (0.75 ng) resulted in some pericardial edema, jaw defects, mild microcephaly and reduced eye development ([Figure 2---figure supplement 1c](#fig2s1){ref-type="fig"}). To avoid potential secondary effects on lymphatics caused by these other abnormalities, we used the 0.5 ng dose for all experiments with the pan-204 MO. At around 36 hpf, vascular 'secondary sprouts' emerge from the cardinal vein, migrate dorsally, pause half-way up the trunk, and then contribute to formation of the parachordal lines (an early transient lymphatic progenitor structure) along the horizontal myoseptum at 2--3 dpf. From 3--5 dpf dorsal and ventral sprouts emerge from the parachordals to give rise to trunk lymphatic network ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}), including the intersegmental lymphatic vessels, dorsal longitudinal lymphatic vessels (DLLV), and thoracic duct ([@bib5]; [@bib60]; [@bib17]). Consistent with previous observations, the secondary sprouts in wild type control animals migrated dorsally to the horizontal myoseptum, turned laterally, and formed the parachordal lines ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---video 1](#fig2video1){ref-type="video"}). Although initial secondary sprout formation and dorsal growth was normal in mir-204-deficient animals, secondary sprouts in these animals failed to stop at the horizontal myoseptum and form the parachordal line, but instead continued to grow dorsally and contributed to veins ([Figure 2d](#fig2){ref-type="fig"} and [Figure 2---video 1](#fig2video1){ref-type="video"}). Examination of the parachordal line at three dpf ([Figure 2e--h,m](#fig2){ref-type="fig"}) showed that compared to control MO-injected animals that had parachordal lines in most somitic segments at this stage ([Figure 2e,f,m](#fig2){ref-type="fig"}), pan-204 MO-injected animals formed parachordals in only about 2 segments per 10 somites ([Figure 2g,h,m](#fig2){ref-type="fig"}). Similarly, examination of the thoracic duct at five dpf ([Figure 2i--l,n](#fig2){ref-type="fig"}) showed that control MO-injected animals had a thoracic duct in virtually all segments ([Figure 2i,j,n](#fig2){ref-type="fig"}) while mir-204-deficient animals displayed nearly complete loss of thoracic duct formation ([Figure 2k,l,n](#fig2){ref-type="fig"}).

![Defective lymphangiogenesis in mir-204 deficient zebrafish.\
(**a**) Sequence alignment of the three zebrafish precursor mir-204 sequences (*mir-204--1, mir-204--2,* and *mir-204--3*) and a schematic diagram showing four morpholinos (pan-204 MO, MO1, MO2, and MO3) targeting them. The data shown in the rest of this figure (panels b-m) uses the pan-204 MO targeting the mature mir-204 sequence generated by all three zebrafish mir-204 loci. (**b**) Quantitative TaqMan RT-PCR measurement of the relative levels of mature miR-204 in one dpf control MO- or pan-204 MO-injected embryos, normalized to controls. Three biological replicates were analyzed. (**c,d**) Time series of confocal images of trunk vessels in 35--51 hpf *Tg(mrc1a:eGFP)^y251^;Tg(kdrl:mCherry)^y171^* control (**c**) or pan-204 morphant (**d**) animals, with secondary sprouts highlighted in green. (**e--h**) Confocal images of the parachordal line in three dpf *Tg(mrc1a:eGFP)^y251^;Tg(kdrl:mCherry)^y171^* animals injected with either control MO (**e, f**) or pan-204 MO (**g, h**). In panel f the parachordal line is highlighted in green and other vessels are in gray. The absence of the parachordal line is noted with asterisks in panels g and h. (**i--l**) Confocal images of the thoracic duct in five dpf *Tg(mrc1a:eGFP)^y251^;Tg(kdrl:mCherry)^y171^* animals injected with either control MO (**i, j**) or pan-204 MO (**k, l**). In panel j the thoracic duct is highlighted in green and other vessels are in gray. The absence of the thoracic duct is noted with asterisks in panels k and l. (**m**) Quantification of parachordal line formation in three dpf animals injected with either control MO (n = 23) or pan-204 MO (n = 32). The same 10 somitic segments were scored in each animal for the presence or absence of an intact parachordal line. (**n**) Quantification of thoracic duct formation in five dpf animals injected with either control MO (n = 25) or pan-204 MO (n = 39). The same 10 somitic segments were scored in each animal for the presence or absence of an intact thoracic duct. All images are lateral views. Scale bar: 50 μm (**c, g, k**). All graphs are analyzed by t-test and the mean ± SD is shown.\
10.7554/eLife.46007.010Figure 2---source data 1.Numerical data for [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.](elife-46007-fig2){#fig2}

mir-204 function is required for lymphatic development {#s2-3}
------------------------------------------------------

To independently confirm our pan-204 MO findings and further examine the relative importance of individual zebrafish mir-204s, we carried out experiments using the MOs independently targeting the dicer-cleavage sites of each of the three zebrafish mir-204s ([Figure 2a](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The sequences targeted by these MOs (MO1, MO2, MO3) differ from one another by 27--46% ([Figure 2---figure supplement 2a](#fig2s2){ref-type="fig"}). Injection of 0.5 ng of each individual MO alone did not affect lymphatic vessel development ([Figure 2---figure supplement 1b--d,i](#fig2s1){ref-type="fig"}). Pairwise co-injection of 0.5 ng MO1 and 0.5 ng MO2 resulted in defective thoracic duct formation ([Figure 2---figure supplement 2e,j](#fig2s2){ref-type="fig"}), but pairwise co-injection of either MO1 + MO3 or MO2 + MO3 did not affect lymphatic vessel formation ([Figure 2---figure supplement 2f,g,j](#fig2s2){ref-type="fig"}). Animals injected with 0.5 ng of each of the three MOs (MO1, MO2, and MO3, for a total of 1.5 ng injected) had lymphatic defects similar to but no more severe than animals injected with either the MO1 + MO2 combination or 0.5 ng of pan-204 MO ([Figure 2---figure supplement 2h,j](#fig2s2){ref-type="fig"} and [Figure 2n](#fig2){ref-type="fig"}). These results suggest that *mir-204--1* and *mir-204--2* play relatively more important roles than *mir-204--3* during lymphatic development, and confirm that suppressing mir-204 function leads to defective lymphatic vessel formation.

To further examine the role of mir-204 in lymphatic development, we generated genetic mutants using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 and CRISPR/Cpf1 systems. Using an active single guide RNA (sgRNA) targeting *mir-204--1* ([Figure 3a](#fig3){ref-type="fig"}), we isolated a 22 bp CRISPR/Cas9 *mir-204--1* deletion mutant that deletes the majority of the mature mir-204 sequence (17 out of 22 nt) and the entire seed sequence at this locus ([Figure 3b](#fig3){ref-type="fig"}). Only an approximately 20% decrease in mir-204 levels in *mir-204--1* homozygous mutants (*miR-204--1^-/-^*) compared to wildtype embryos suggests that reduction from *mir-204--1* loss is compensated for by *mir-204--2* and/or *mir-204--3* ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). The *mir-204--1^-/-^* animals were viable and fertile and did not have obvious morphological defects up to adulthood ([Figure 3c,d](#fig3){ref-type="fig"} and data not shown). Entirely consistent with the data generated exclusively using morpholinos ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), *mir-204--1^-/-^* mutant animals injected with either MO2 ([Figure 3e,h](#fig3){ref-type="fig"}) or with MO2+MO3 ([Figure 3g,h](#fig3){ref-type="fig"}) fail to properly form the thoracic duct and other lymphatic vessels, but *mir-204--1^-/-^* mutants injected with MO3 developed normal lymphatics ([Figure 3f,h](#fig3){ref-type="fig"}). MO2-injected *mir-204--1^-/-^* mutant animals also showed defects in earlier parachordal line formation ([Figure 3---figure supplement 1b--d](#fig3s1){ref-type="fig"}), like pan-204 MO-injected animals ([Figure 2g,h,m](#fig2){ref-type="fig"}). These data indicate that suppressing biogenesis of mir-204 from the *mir-204--1* and *mir-204--2* loci is sufficient to disrupt mir-204 function in lymphatic vessel formation, regardless of whether a genetic mutant or morpholino is used to suppress *miR-204--1.*

![Mir-204 function is required for lymphatic development.\
(**a**) Schematic of CRISPR/Cas9 and guide RNA targeting of *mir-204--1*. (**b**) Sequence alignment of wildtype and *mir-204--1* mutant genomic DNA. The mature mir-204 sequence is noted in magenta, and the PAM sequence is highlighted in red (on the reverse strand). The mutant carries 22 bp deletion that removes 17 nucleotides of the mature mir-204 sequence. (**c--g**) Representative confocal images of the mid-trunk of 5 dpf wild type sibling (**c**), *mir-204--1^-/-^* mutant (**d**), MO2-injected *mir-204--1^-/-^* mutant (**e**), MO3-injected *mir-204--1^-/-^* mutant (**f**), and MO2 + MO3 co-injected *mir-204--1^-/-^* mutant (**g**) animals. Images are lateral views of *Tg(mrc1a:eGFP)^y251^, Tg(kdrl:mCherry)^y171^* double-transgenic animals, rostral to the left. The thoracic duct is labeled with white arrows, and absence of the thoracic duct is noted with asterisks. (**h**) Quantification of thoracic duct formation in five dpf wild type (n = 6), *mir-204--1^-/-^* mutant (n = 9), MO2-injected *mir-204--1^-/-^* mutant (n = 23), MO2-injected *mir-204--1^-/-^* mutant (n = 19), and MO2 + MO3 co-injected *mir-204--1^-/-^* mutant animals (n = 25). The number of somitic segments with an intact thoracic duct was counted, with the same seven mid-trunk somites measured in each animal. Scale bar: 100 μm (**c**). All graphs are analyzed by t-test and the mean ± SD is shown.\
10.7554/eLife.46007.015Figure 3---source data 1.Numerical data for [Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.](elife-46007-fig3){#fig3}

We also used CRISPR/Cpf1 targeting to generate −11 bp and −17 bp deletion mutations for *mir-204--2* and a −12 bp deletion for *mir-204--3* ([Figure 3---figure supplement 2a](#fig3s2){ref-type="fig"}). Since *mir-204--1^-/-^* animals are viable and fertile, we co-injected two separate sgRNAs targeting *mir-204--2* and *mir-204--3*, respectively, into *mir-204--1^-/-^* embryos to facilitate generation of *mir-204* triple mutants. We obtained triple mutants deleting the seed sequences of all three mir-204s ([Figure 3---figure supplement 2a](#fig3s2){ref-type="fig"}). Although expression of mir-204 was strongly reduced in *mir-204* triple homozygous mutants ([Figure 3---figure supplement 2b](#fig3s2){ref-type="fig"}), they did not display statistically significant lymphatic defects ([Figure 3---figure supplement 2c--e](#fig3s2){ref-type="fig"}), presumably due to an unknown compensatory mechanism taking place in animals where all genomic mature *mir-204* sequences are defective.

Endothelial expression of mir-204 drives precocious lymphangiogenesis {#s2-4}
---------------------------------------------------------------------

To further confirm and examine the role of mir-204 in lymphatics, we used the mrc1a promoter ([@bib23]) to drive mir-204 expression in venous and lymphatic endothelial cells using a previously described transgene vector for microRNA expression ([@bib40]) containing splice donor (SD) and splice acceptor (SA) sequences from the EF1alpha gene, with the *dre-mir-204--1-*containing trpm3 intron five sequence cloned in between them ([Figure 4a](#fig4){ref-type="fig"}). As a control, we introduced a 4 bp mismatch into the seed sequence position 2--5 (TCCC to AGGG) using site-directed mutagenesis ([Figure 4b](#fig4){ref-type="fig"}). We injected *mrc1a:mir204(4 bp_seed_mut)-eGFP* (as control) or *mrc1a:mir204-eGFP* vector DNA into single-cell wild type embryos and analyzed the mosaic contribution to thoracic duct formation at three dpf, when the cells from parachordal line start to migrate ventrally to form thoracic duct. In comparison to control embryos that were just beginning thoracic duct formation ([Figure 4b](#fig4){ref-type="fig"}), embryos injected with *mrc1a:mir204-eGFP* formed a significantly increased number of thoracic duct segments ([Figure 4c](#fig4){ref-type="fig"}) suggesting that endothelial expression of mir-204 promotes early thoracic duct development ([Figure 4d](#fig4){ref-type="fig"}). We also isolated germline transgenic animals carrying this *Tg(mrc1a:mir204-egfp)* transgene. Similar to the results from the mosaic analysis, germline transgenic progeny generated from these fish display precocious development of the thoracic duct ([Figure 4---figure supplement 1a--c](#fig4s1){ref-type="fig"}). These animals are viable and fertile with no obvious morphological abnormalities or other defects, including normal stage-specific spacing between the dorsal aorta and posterior cardinal vein ([Figure 4---figure supplement 1d](#fig4s1){ref-type="fig"}), despite an approximately 2-fold increase in mature miR-204 levels measured by qPCR at three dpf ([Figure 4---figure supplement 1e](#fig4s1){ref-type="fig"}). These results suggest that increased endothelial mir-204 expression specifically promotes early lymphatic development.

![Endothelial expression of mir-204 drives precocious lymphatic development and rescues the loss-of-lymphatic phenotype in mir-204-deficient animals.\
(**a**) Schematic illustration of the mir-204 expression construct. The EGFP expression cassette is driven by the *mrc1a* promoter ([@bib23]), with \~1 kb of *dre-miR-204--1* genomic sequence from the fifth intron of the *trpm3* gene cloned between splice donor (SD) and splice acceptor (SA) sequences and flanking exonic sequences from the *ef1a* gene. The original vector backbone was previously described ([@bib40]). As a control, a 4 bp mismatch mutation was introduced in the seed (underline) sequence of mature mir-204 sequence. The construct was injected into 1 cell stage embryos to examine the mosaic endothelial expression. (**b,c**) Representative confocal images of mid-trunk of 3 dpf embryos injected with (**b**) control *mrc1a:mir204(4 bp_seed_mut)-eGFP* DNA or (**c**) *mrc1a:mir204-eGFP* DNA. The thoracic duct is pseudocolored in green, with other vessels in gray. (**d**) Quantification of thoracic duct formation in animals injected with either *mrc1a:eGFP* control or *mrc1a:mir204-eGFP* DNA. (**e--g**) Confocal images of *Tg(mrc1a:eGFP)^y251^, Tg(kdrl:mCherry)^y171^* double-transgenic MO2-injected *mir-204--1^-/-^* mutant animals without (**e**) or with (**f,g**) co-injected *mrc1a:mir204-eGFP* DNA. (**h--j**) Cropped portions of the corresponding images in e-g, with the thoracic duct pseudocolored in green and other nearby vessels in gray. (**k**) Quantification of thoracic duct formation in animals as in panels e-g. The number of somitic segments with an intact thoracic duct was counted, with the same seven mid-trunk somites measured in each animal. Scale bar: 100 μm (**c,e**). All graphs are analyzed by t-test and the mean ± SD is shown.\
10.7554/eLife.46007.018Figure 4---source data 1.Numerical data for [Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.](elife-46007-fig4){#fig4}

To further confirm the endothelial cell autonomous role of miR-204 in lymphatic development, we examined whether endothelial specific miR-204 expression could also rescue the loss-of-lymphatic phenotype in mir-204-deficient animals. Since the transgene construct was generated using *mir-204--1* genomic sequence, MO2 (which specifically targets mir-204--2) does not affect its function ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2a](#fig2s2){ref-type="fig"}). Combined loss of mir-204--1 and mir-204--2 is sufficient for the full miR-204 lymphatic phenotype ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4e](#fig4){ref-type="fig"}). MO2-injected *mir-204--1^-/-^* embryos showed strong suppression of thoracic duct formation ([Figure 4e,h,k](#fig4){ref-type="fig"}), but this was rescued by co-injection of the mrc1a:miR204-eGFP transgene ([Figure 4f,g,i,j,k](#fig4){ref-type="fig"}), with stronger 'rescue' noted in animals with a higher mosaic contribution from the transgene ([Figure 4g,j,k](#fig4){ref-type="fig"}). Together, these data indicate that endothelial-autonomous miR-204 function is required for developmental lymphangiogenesis.

NFATC1 is a conserved target of miR-204 {#s2-5}
---------------------------------------

Based on our observation that this microRNA plays an important role during lymphatic development, we began a search for potential miR-204 target genes required for developmental lymphangiogenesis. We (i) began with a list of human genes previously implicated in lymphatic development, then (ii) bioinformatically identified which genes in this set had potential miR-204 target sites using TargetScan ([@bib1]), and then (iii) bioinformatically identified which of these genes also had corresponding zebrafish orthologs with potential miR-204 target sites (in order to ensure that we were looking at key, conserved targets that we could functionally study in both human cell culture and in zebrafish ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The Nuclear Factor of Activated T Cells 1 (NFATC1) gene immediately came to our attention as a strong candidate meeting these criteria.

NFATC1 is expressed in developing lymphatic endothelial cells and genetic ablation of Nfatc1 in mice causes abnormal lymphatic vessel patterning and lymphatic hyperplasia ([@bib42]). Human NFATC1 contains a putative miR-204 binding site in its 3'UTR ([Figure 5a](#fig5){ref-type="fig"}). The NFATC1 3′UTR was cloned downstream of a luciferase reporter and this plasmid DNA construct was co-transfected into HEK293 cells together with either miR-204 or (as a negative control) miR-126. Luciferase reporter activity was significantly suppressed in the presence of miR-204 but not in the presence of the miR-126 control ([Figure 5b](#fig5){ref-type="fig"}). To confirm the specificity of NFATC1 miR-204 target site recognition, we mutated four nucleotides in the seed binding sequence of the NFATC1 3'UTR ([Figure 5a](#fig5){ref-type="fig"}) and demonstrated that this rendered the construct insensitive to suppression by miR-204 ([Figure 5b](#fig5){ref-type="fig"}), confirming that this binding site is critical for direct targeting. Overexpression of miR-204 in human LECs suppressed endogenous NFATC1 expression while miR-204 inhibitor (antagomir) increased endogenous NFATC1 expression, showing that miR-204 also regulates endogenous NFATC1 transcript levels in human LEC ([Figure 5c](#fig5){ref-type="fig"}). We observed similar regulation of nfatc1 by mir-204 in the zebrafish. Zebrafish *nfatc1* also contains a mir-204 binding site in its 3'UTR ([Figure 5d](#fig5){ref-type="fig"}). The activity of a luciferase reporter containing the zebrafish *nfatc1* 3'UTR is also strongly suppressed by miR-204, and this suppression is fully rescued by mutating the seed binding sequence in the nfatc1 3'UTR ([Figure 5e](#fig5){ref-type="fig"}). Importantly, mir-204 knockdown using the pan-204 MO (targeting all three zebrafish mir-204s) results in increased levels of endogenous nfatc1 transcript in five dpf zebrafish embryos ([Figure 5f](#fig5){ref-type="fig"}). Together, these data demonstrate conserved miR-204-mediated regulation of NFATC1.

![NFATC1 is a conserved target of miR-204.\
(**a**) Sequence alignment of mature miR-204 (middle line) and its target region in the human NFATC1 3'UTR (top line). A mutant form of the human NFATC1 3'UTR used for the luciferase assay in panel b is also shown (bottom line; four mismatches in the seed binding region are highlighted in red). (**b**) Quantitative luciferase reporter assay using wild type or mutant forms of the human NFATC1 3'UTR transfected into HEK293 cells together with either miR-204 or miR-126 (control). Four biological replicates were analyzed. (**c**) Quantitative TaqMan RT-PCR measurement of relative endogenous NFATC1 transcript levels in human LEC (HMVEC-dLy) transfected with miR-204-mimic or miR-204-antagomir, normalized to control mock transfected levels. (**d**) Sequence alignment of mature miR-204 (middle line) and its target region in the zebrafish nfatc1 3'UTR (top line). A mutant form of the zebrafish nfatc1 3'UTR used for the luciferase assay in panel e is also shown (bottom line; four mismatches in the seed binding region are highlighted in red). (**e**) Quantitative luciferase reporter assay using wildtype or mutant forms of the zebrafish nfatc1 3'UTR co-transfected into HEK293 cells together with either miR-204 or miR-126 (control). Four biological replicates were analyzed. (**f**) Quantitative TaqMan RT-PCR measurement of relative endogenous zebrafish nfatc1 transcript levels in five dpf animals that were injected with either control MO or pan-204 MO. Three biological replicates were analyzed. All graphs are analyzed by t-test and the mean ± SD is shown.\
10.7554/eLife.46007.020Figure 5---source data 1.Numerical data for [Figure 5](#fig5){ref-type="fig"}.](elife-46007-fig5){#fig5}

Suppression of NFATC1 causes thoracic duct hyperplasia in the zebrafish {#s2-6}
-----------------------------------------------------------------------

As noted above, loss of Nfatc1 in mice is associated with lymphatic hyperplasia ([@bib42]). Using two different morpholinos targeting *nfatc1* (splice MO and ATG MO), we show that knockdown of this gene in the zebrafish also causes thoracic duct enlargement, similar to that shown in mice, with no noticeable abnormal blood vessel formation ([Figure 6a--e](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1a--e](#fig6s1){ref-type="fig"}). The calcineurin inhibitor cyclosporin A (CsA) blocks signaling downstream from NFAT, and treatment of mice with CsA during embryonic stages phenocopies the lymphatic effects caused by genetic ablation of Nfatc1 ([@bib42]). The zebrafish larvae treated with a low doses of CsA (1 ug/mL) also displayed thoracic duct enlargement phenotype observed in nfatc1 MO-injected animals ([Figure 6---figure supplement 1f--j](#fig6s1){ref-type="fig"}). We used CRISPR/Cas9 mutagenesis to generate −8 bp frameshift mutation in the *nfatc1* gene with premature stop codons producing truncated nfatc1 polypeptides lacking key functional domains ([Figure 6f](#fig6){ref-type="fig"}). Like nfatc1 morphants and CsA-treated animals, *nfatc1^△8/△8^* mutants also had enlarged thoracic ducts at five dpf ([Figure 6g--k](#fig6){ref-type="fig"}). Therefore, consistent with previous data in mice, our results suggest that nfatc1 is required for proper lymphatic development in the zebrafish.

![Suppression of Nfatc1 promotes enlargement of the thoracic duct.\
(**a,b**) Confocal images of the mid-trunk of 5 dpf *Tg(mrc1a:eGFP)^y251^, Tg(kdrl:mCherry)^y171^* double-transgenic control MO (**a**) or nfatc1 splice MO (**b**) injected animals. The dashed boxes in panels a and b show the areas magnified in panels c and d, respectively. (**c,d**) Magnified images from panels a and b, with the thoracic duct pseudocolored in green and other vessels in gray. (**e**) Quantitation of thoracic duct size measured as the area encompassed by the thoracic duct in confocal images of the same seven mid-trunk somitic segments in five dpf wildtype (n = 9) and nfatc1 MO-injected (n = 9) animals. (**f**) Sequence alignment of wildtype and *nfatc1^△8/△8^* mutant genomic DNA. Schematic of nfatc1 protein domains, CRISPR target site, and truncated mutant nfatc1 polypeptides. (**g,h**) Confocal images of the mid-trunk of 5 dpf *Tg(mrc1a:eGFP)^y251^* wildtype (**g**) or *nfatc1^△8/△8^* mutant (**h**) animals. (**i,j**) Magnified images from panels g and h, with the thoracic duct pseudocolored in green and other vessels in gray. (**k**) Quantitation of thoracic duct size measured as the area encompassed by the thoracic duct in confocal images of the same seven mid-trunk somitic segments in five dpf wildtype (n = 8) and *nfatc1^△8/△8^* mutant (n = 10) animals. Rostral is to the left in all images. Scale bar = 100 μm (**b,d,g,i**). All graphs are analyzed by t-test and the mean ± SD is shown.\
10.7554/eLife.46007.023Figure 6---source data 1.Numerical data for [Figure 6](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.](elife-46007-fig6){#fig6}

Suppression of nfatc1 rescues lymphatic development in mir-204-deficient zebrafish {#s2-7}
----------------------------------------------------------------------------------

The results above suggest that increased expression of nfatc1 might be at least partially responsible for the defects in lymphatic vessel development in mir-204-deficient animals. To test this idea, we examined whether lymphatic vessel formation in mir-204-deficient animals could be 'rescued' by nfatc1 knockdown. As already described above, pan-204 MO-injected animals fail to form the thoracic duct ([Figure 7a,b,d,e,j](#fig7){ref-type="fig"}) and dorsal longitudinal lymphatic vessel (DLLV) in the trunk ([Figure 7a,b,g,h,k](#fig7){ref-type="fig"}). However, in animals co-injected with both pan-204 MO and nfatc1 splice MO, formation of the thoracic duct is largely restored ([Figure 7c,f,j](#fig7){ref-type="fig"}), as is the formation other lymphatic vessels including the DLLV and intersegmental lymphatics (ISLV) ([Figure 7c,i,k](#fig7){ref-type="fig"}). These results suggest that abnormal lymphatic vessel development in mir-204 deficient animals can be substantially rescued by suppressing nfatc1 expression. Based on all of our findings, we propose that a proper balance between mir-204 and nfatc1 is critical for proper lymphatic vessel development, with loss of either mir-204 or nfatc1 causing defects in lymphatic vessel formation ([Figure 7l](#fig7){ref-type="fig"}).

![Suppression of nfatc1 rescues the lymphatic defects in mir-204-deficient animals.\
(**a--c**) Confocal images of the mid-trunk of 5 dpf control (**a**) pan-204 MO-injected (**b**) or pan-204 MO and nfatc1 splice MO co-injected (**c**) animals. White dotted boxes in panels a-c show areas magnified in panels d-f, respectively, while white dashed boxes show areas magnified in panels g-i, respectively. (**d--f**) Magnified images from panels a-c with the thoracic duct (TD) pseudocolored in green and other vessels in gray. The TD is labeled, and the absence of the TD is noted with asterisks. (**g--i**) Magnified images from panels a-c with the dorsal longitudinal lymphatic vessel (DLLV) pseudocolored in green and other vessels in gray. The DLLV is labeled, and the absence of the DLLV is noted with asterisks. (**j**) Quantification of thoracic duct (TD) formation in five dpf control (n = 8), pan-204 MO-injected (n = 19), or pan-204 MO and nfatc1 splice MO co-injected animals (n = 21). A total of 7 mid-trunk somitic segments were scored in each animal for the presence or absence of an intact TD. (**k**) Quantification of dorsal longitudinal lymphatic vessel (DLLV) formation in five dpf control (n = 8), pan-204 MO-injected (n = 19), or pan-204 MO and nfatc1 splice MO co-injected animals (n = 21). A total of 7 mid-trunk somitic segments were scored in each animal for the presence or absence of an intact DLLV. (**l**) Schematic diagrams illustrating five dpf zebrafish trunk lymphatic vessels present in (**i**) normal control, (ii) mir-204 deficient, (iii) nfatc1-deficient, and (iv) mir-204- and nfatc1-deficient animals. Suppression of mir-204 leads to loss of lymphatic vessels (ii), while nfatc1 deficiency causes lymphatic (thoracic duct) hyperplasia (iii). The lymphatic defects in mir-204 deficient animals can be rescued by simultaneous suppression of nfatc1 (iv). All images are lateral views of *Tg(mrc1a:eGFP)^y251^, Tg(kdrl:mCherry)^y171^* double-transgenic animals, rostral to the left. Scale bar = 100 μm (**c,i**). All graphs are analyzed by t-test and the mean ± SD is shown.\
10.7554/eLife.46007.025Figure 7---source data 1.Numerical data for [Figure 7](#fig7){ref-type="fig"}.](elife-46007-fig7){#fig7}

Discussion {#s3}
==========

Although transcriptional programs directing lymphatic vessel formation have been described in recent years ([@bib59]; [@bib9]; [@bib24]; [@bib15]; [@bib48]; [@bib61]; [@bib54]; [@bib17]; [@bib32]; [@bib51]; [@bib4]; [@bib7]), the post-transcriptional steps that help to refine this tightly regulated process remain largely unexplored. In this study, we identified LEC-enriched microRNAs by comparing the small RNA profiles of human primary blood (HUVEC) or lymphatic (HMVEC-dLy) endothelial cells. Both of these cells have been previously well-validated as having representative blood endothelial cell (BEC) and or lymphatic endothelial cell (LEC) gene expression profiles ([@bib34]; [@bib10]), and we confirmed that they have appropriate differential expression of well-characterized markers of blood and lymphatic endothelial identity. The majority of the 30 highly significantly LEC-enriched microRNAs we identified were specific to mammals, with only seven microRNAs conserved in other vertebrate species. This suggests that most of these LEC microRNAs have diverged and/or evolved for mammalian-specific functions. The most highly LEC-enriched microRNA was miR-204, a microRNA with 100% sequence identity across a broad swath of vertebrate species ([Figure 2---figure supplement 2a](#fig2s2){ref-type="fig"}), suggesting it plays an important conserved role during lymphatic development. In addition to miR-204 and a number of other newly identified LEC-enriched microRNAs, we also uncovered microRNAs such as miR-326, miR-139, miR-338, miR-148a, and miR-30d that had been previously reported to be LEC-enriched ([@bib34]). Intriguingly, miR-204 was not identified in the previous study by Pedrioli et al, despite its being the most highly enriched lymphatic microRNA in our study, while the most enriched LEC microRNA reported by Pedrioli et al, miR-95, was excluded from our analysis due to a low number of sequence reads. The reasons for the disparate results obtained from our data set and that of Pedrioli et al. are not clear, but they may reflect differences in the starting material for sequencing, the profiling methods used, or the bioinformatic tools and filters employed. We would note that out study used three biological replicates for both the LEC and BEC sequencing, and that we sequenced to a relatively high depth and applied very stringent filtering to our data set. Our FACS sorting data confirmed very strong enrichment of miR-204 in zebrafish lymphatic vs. blood endothelial cells. Although we were not able to detect this microRNA in zebrafish using previously reported whole mount in situ hybridization methods ([@bib58]), detection of microRNAs in zebrafish using this method is difficult and frequently unsuccessful, especially for mid- or low-copy microRNAs ([@bib29]).

The remarkable evolutionary conservation of the miR-204 sequence throughout the vertebrates suggests that this microRNA likely plays an important conserved function. Indeed, our zebrafish findings show that suppression of mir-204 leads to strong defects in developmental lymphangiogenesis. Although the sequence of mature zebrafish mir-204 is identical to human miR-204, human miR-204 is encoded by only a single locus in intron 6 of the TRPM3 gene, while zebrafish mir-204 is encoded by three separate loci within the introns of the *trpm3, trpm1a,* and *trpm1b* genes. Interestingly, however, the mammalian *TRPM1* gene has a related microRNA encoded within a similar intron to zebrafish *trpm1a* and *trpm1b,* that may have evolved from mir-204. We demonstrated the essential role of miR-204 in developmental lymphangiogenesis using multiple complementary loss-of-function approaches, including (i) a 'pan-204' morpholino targeting the mature mir-204 sequence produced by all three zebrafish mir-204 loci, (ii) morpholinos individually targeting sequences required for the maturation of each of the three zebrafish mir-204's (MO1, MO2, and MO3), and (iii) a CRISPR-Cas9-generated genetic mutant ablating the *mir-204--1* locus, which caused a lymphatic defect in combination with MO2 (targeting miR-204--2). Our results revealed that treatments that target at minimum *mir-204--1* and *mir-204--2* result in comparable dramatic loss-of-lymphatic phenotypes, including loss of the parachordal line at three dpf and loss of the thoracic duct and other trunk lymphatic vessels at five dpf.

Our endothelial-specific transgenic miR-204 expression experiments confirm the important role of miR-204 in lymphatic development in the zebrafish, and further indicate that this role reflects endothelial-autonomous function of this microRNA. Wild type animals injected with mrc1a:mir204-1-eGFP transgene display precocious thoracic duct development, as do germline transgenic animals carrying the transgene inserted into the genome. Importantly, the mrc1a:mir204-1-eGFP transgene also 'rescues' thoracic duct formation when introduced into miR-204--1^-/-^ mutants injected with MO2 (targeting miR-204--2) that would otherwise lack lymphatics, demonstrating that re-introduction of miR-204 exclusively in the endothelium is sufficient to restore normal lymphatic development in miR-204-deficient animals. Despite all of these interlocking findings strongly arguing for a key role for miR-204 in lymphatic development, triple mutants disrupting all three zebrafish miR-204 loci do not display a significantly measurable lymphatic defect. Although the reasons for this are unclear, there is precedent in the literature for zebrafish microRNA mutants failing to exhibit the full phenotypes noted in microRNA knockdown studies. Suppression of the evolutionarily conserved endothelial-enriched microRNA mir-126 causes blood vessels defects in mir-126 morpholino-injected animals ([@bib13]) ([@bib62]), although lower dose morpholino injections cause mainly lymphatic defects with relatively minor effects on blood vessels ([@bib6]). Interestingly, mir-126 mutant zebrafish also lack the vascular phenotype described in the previous morpholino studies and display only the defects in lymphatic vessel development seen with partial knockdowns ([@bib28]), suggesting compensation may be taking place in miR-126 mutants.

In addition to uncovering an important function for miR-204, our study also identified a key downstream target of miR-204 regulation during lymphangiogenesis. Previous studies have shown that the Nuclear Factor of Activated T-cells (NFAT) protein family member NFATC1 is important for lymphatic vessel development ([@bib42]; [@bib32]). Nfatc1 is co-expressed with Prox1-, Vegfr3-, and Pdpn-positive LEC progenitors originating from the cardinal vein indicating their potential involvement in lymphatic specification, and Nfatc1 null mice develop lymphatic hyperplasia suggesting a role in lymphatic maturation ([@bib42]; [@bib32]). Consistent with these previous data, we showed that nfatc1 mutation, nfatc1 knockdown, or pharmacologically blocking nfatc1 activity results in similar lymphatic enlargement in the zebrafish. We identified NFATC1 as a probable miR-204 target based on conserved miR-204 binding sites in the 3' UTRs of both human and zebrafish NFATC1 transcripts and the expression of NFATC1 was suppressed by miR-204 mimic and increased by miR-204 antagomir in human LECs. We were able to verify targeting of the NFATC1 3' UTR by miR-204 using firefly/renilla dual luciferase NFATC1 3' UTR reporter assays, and demonstrate up-regulation of zebrafish nfatc1 upon mir-204 knockdown, confirming that miR-204 suppresses NFATC1 levels in vivo. Finally, we showed that knocking down nfatc1 could rescue lymphatic development in mir-204-deficient zebrafish, suggesting that balanced expression of mir-204 and nfatc1 is critical for proper developmental lymphangiogenesis.

Since microRNAs often regulate many targets, and miR-204 does have potential target binding sites in other genes, further investigation will be required to characterize some of these additional genes and determine whether some of the lymphatic effects of miR-204 are mediated via regulation of other targets in addition to nfatc1. Nevertheless, since (i) NFATC1 has already been shown to play an important role in lymphangiogenesis in mammals, (ii) suppression of nfatc1 in the zebrafish causes lymphatic hyperplasia, and (iii) nfatc1 knockdown effectively rescues the effects of miR-204 knockdown, our results suggest that nfatc1 is a major, key downstream target regulated by miR-204 in developing lymphatic endothelial cells.

In summary, our work establishes an important role for miR-204 in regulating lymphatic vascular network formation during embryonic development via modulation of its conserved target NFATC1. Our findings provide important new insight into the role of lymphatic-enriched microRNAs during developmental lymphangiogenesis, and by unveiling microRNA-regulated pathways provide new opportunities to understand lymphatic development and associated disorders.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                  Designation                                         Source or reference                                              Identifiers                                                    Additional\
  (species) or resource                                                                                                                                                                                              information
  ------------------------------ --------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------------------------------------------
  Genetic reagent (*D. rerio*)   Tg(mrc1a:eGFP^y251^; kdrl:mCherry^y171^)            PMID: [28506987](https://www.ncbi.nlm.nih.gov/pubmed/28506987)   ZFIN ID: ZDB-TGCONSTRCT-170717--2                              

  Genetic reagent (*D. rerio*)   Tg(mrc1a:eGFP^y251^)                                PMID: [28506987](https://www.ncbi.nlm.nih.gov/pubmed/28506987)   ZFIN ID: ZDB-TGCONSTRCT-170717--2                              

  Genetic reagent (*D. rerio*)   Tg(mrc1a:mir204-eGFP)                               This paper                                                                                                                      

  Genetic\                       mir-204--1^-/-^; mir-204--2^-/-^; mir-204--3^-/-^   This paper                                                                                                                      
  reagent (*D. rerio*)                                                                                                                                                                                               

  Genetic reagent (*D. rerio*)   nfatc1^△8/△8^                                       This paper                                                                                                                      

  Cell line (*H. sapiens*)       HMVEC-dLy                                           Lonza                                                            Cat\# CC-2812                                                  

  Cell line (*H. sapiens*)       HUVEC                                               GIBCO                                                            Cat\# C-003--5C                                                

  Cell line (*H. sapiens*)       HEK293                                              ATCC                                                             Cat\# CRL-1573\                                                
                                                                                                                                                      RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)     

  Recombinant DNA                pME-mir204                                          This paper                                                                                                                      Used pME-miR for backbone vector (PMID: [2914488](https://www.ncbi.nlm.nih.gov/pubmed/2914488))

  Recombinant DNA                mrc1a:mir204-eGFP                                   This paper                                                                                                                      

  Recombinant DNA                mrc1a:mir204(4 bp_seed_mut)-eGFP                    This paper                                                                                                                      

  Recombinant DNA                psiCheck2-\                                         This paper                                                                                                                      Used for luciferase assay
                                 hNFATC1-3'UTR                                                                                                                                                                       

  Recombinant DNA                psiCheck2-hNFATC1-3'UTR_4 bp_mut                    This paper                                                                                                                      Used for luciferase assay

  Recombinant DNA                psiCheck2-zNFATC1-3'UTR                             This paper                                                                                                                      Used for luciferase assay

  Recombinant DNA                psiCheck2-zNFATC1-3'UTR_4 bp_mut                    This paper                                                                                                                      Used for luciferase\
                                                                                                                                                                                                                     assay

  Sequence-based reagent         Cloning primers                                     This paper                                                                                                                      See [Supplementary file 2a](#supp2){ref-type="supplementary-material"} for sequence information

  Sequence-based reagent         Morpholinos                                         This paper                                                                                                                      See [Supplementary file 2b](#supp2){ref-type="supplementary-material"}\
                                                                                                                                                                                                                     for\
                                                                                                                                                                                                                     sequence information

  Sequence-based reagent         gRNAs                                               This paper                                                                                                                      See\
                                                                                                                                                                                                                     [Supplementary file 2c](#supp2){ref-type="supplementary-material"}\
                                                                                                                                                                                                                     for\
                                                                                                                                                                                                                     sequence information

  Sequence-based reagent         hsa-miR-204--5 p mimic                              Thermo Fisher Scientific                                         Cat\# MC11116                                                  

  Sequence-based reagent         hsa-miR-204--5 p inhibitor                          Thermo Fisher Scientific                                         Cat\# MH11116                                                  

  Sequence-based reagent         hsa-miR-126--3 p mimic                              Thermo Fisher Scientific                                         Cat\# MC12841                                                  

  Chemical compound, drug        Cyclosporine A                                      Sigma-Aldrich                                                    Cat\# PHR1092                                                  

  Septide, recombinant protein   EnGen Lba Cas12a (Cpf1)                             New England Biolabs                                              Cat\# M0653T                                                   

  Software,\                     ImageJ                                              ImageJ (<http://imagej.nih.gov/ij/>)                             RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)   
  algorithm                                                                                                                                                                                                          

  Software, algorithm            Imaris                                              Bitplane                                                         RRID:[SCR_007370](https://scicrunch.org/resolver/SCR_007370)   

  Software, algorithm            Adobe Photoshop                                     Adobe                                                            RRID:[SCR_014199](https://scicrunch.org/resolver/SCR_014199)   

  Software, algorithm            NIS-Elements                                        Nikon                                                            RRID:[SCR_014329](https://scicrunch.org/resolver/SCR_014329)   

  Software,\                     GraphPad Prism                                      GraphPad Prism (<https://graphpad.com>)                          RRID:[SCR_015807](https://scicrunch.org/resolver/SCR_015807)   
  algorithm                                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Zebrafish and drug treatment {#s4-1}
----------------------------

Zebrafish husbandry and research protocols were reviewed and approved by the NICHD Animal Care and Use Committee at the National Institutes of Health (Animal Research Assurance Number: A4149-01). All animal studies were carried out according to NIH-approved protocols (Animal Study Proposal: \#18--015), in compliance with the *Guide for the Care and use of Laboratory Animals*. Zebrafish were maintained and zebrafish experiments were performed according to standard protocols ([@bib57]). The *Tg(mrc1a:eGFP)^y251^;Tg(kdrl:mCherry)^y171^* double transgenic line was used in this study ([@bib23]). For nfatc1 inhibition, 24 hpf embryos were dechorinated and incubated in 1 ug/mL cyclosporine A (CsA) or DMSO for 4 days and the animals imaged at five dpf.

Transgenic constructs and animals {#s4-2}
---------------------------------

The *Tol2(mrc1a:mir204-eGFP)* venous/lymphatic endothelial autonomous expression construct was generated using Tol2kit components with Gateway Technology ([@bib33]). To make a *mir-204* middle entry cassette for the overexpression construct, we used pME-miR, containing an partial EF1alpha gene exon 1, intron 1, and exon 2 ([@bib40]). A 1 kb genomic DNA sequence from intron 5 of the *trpm3* gene harboring the *mir-204--1* precursor was amplified by PCR and subcloned into the multiple cloning site located in EF1alpha intron 1 of pME-miR using Kpn1 and EcoR1, to generate pME-mir204. To generate the final venous/lymphatic endothelial autonomous mir-204 expression construct, we combined p5E-mrc1a ([@bib23]), pME-mir204, p3E-EGFPpA ([@bib33]), and pDestTol2pA ([@bib33]). Mutations in the miR-204 seed sequence were generated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and the sequences were confirmed by DNA sequencing. The DNA construct was microinjected into one-cell stage zebrafish embryos to generate transgenic insertions. Injected animals were either analyzed during early development or raised to adulthood and their progeny screened for germline transmission and expression of the transgene. All oligos used for cloning are listed ([Supplementary file 2a](#supp2){ref-type="supplementary-material"}).

Flow cytometry {#s4-3}
--------------

All embryos subjected to FACS sorting were raised in E3 medium. five dpf *Tg(mrc1a:egfp)^y251^, Tg(kdrl:mcherry)^y171^* double transgenic zebrafish were anesthetized with MS-222 and washed with 1X PBS (pH 7.4, without Ca^2+^ and Mg^2+^) three times. Animals were deyolked by gentle pipetting in yolk dissociation solution (55 mM NaCl, 1.8 mM KCl, 1.25 mM NaHCO~3~). Cells were then dissociated by gentle pipetting in 0.25% trypsin-EDTA and 50 mg/mL collagenase solution. Dissociated cells were passed though 70 μm filter and centrifuged at 4000 rpm for 5 min at room temperature. Cells were washed and resuspended with 1X PBS. Fluorescent cell sorting was performed on a BD FACS ARIA (Becton Dickinson, Franklin Lakes, NJ). Isolated GFP+, mCherry+, and double positive cells were pelleted at 2,500 rpm for 5 min.

Morpholino injections {#s4-4}
---------------------

All morpholinos (MOs) used in this study were acquired from Gene Tools. The nfatc1 splice MO sequence was described in a previous study ([@bib53]). MOs were injected into one cell stage *Tg(mrc1a:egfp)^y251^, Tg(kdrl:mcherry)^y171^* double transgenic zebrafish embryos ([@bib23]). Injected embryos were allowed to develop at 28.5°C before being imaged at the desired stage. Morpholino doses used were determined by performing dose curves to establish the optimal dose to minimize off-target effects. The doses used in this study were 0.5 ng for all mir-204 MOs (pan-204, MO1, MO2, and MO3), 3 ng for nfatc1 splice MO, and 7.5 ng for nfatc1 ATG MO. All morpholino sequences are listed ([Supplementary file 2b](#supp2){ref-type="supplementary-material"}).

Genome editing {#s4-5}
--------------

CRISPR genome editing technology was used to generated miR-204 mutants. In order to use the most efficient editing by finding the optimal protospacer adjacent motif (PAM) sequence, Cas9 was used to target *dre-miR-204--1* and Cpf1 (Cas12a) was used to target *dre-miR-204--2* and *dre-miR-204--3.* The codon-optimized Cas9 plasmid pT3TS-nls-zCas9-nls was used as template to in vitro transcribe Cas9 mRNA ([@bib19]) and we used commercially available Cpf1 protein (New England Biolabs) as described ([@bib12]; [@bib38]). Single guide RNAs (sgRNAs) were designed to target each precursor *mir-204* sequence using CRISPRscan ([www.crisprscan.org](http://www.crisprscan.org)) ([@bib37]). The sgRNA for *mir-204--1* was in vitro synthesized using T7 promoter, and sgRNAs for *mir-204--2* and *mir-204--3* were obtained from Integrated DNA Technologies (IDT). Fluorescence PCR was performed using AmpliTaq Gold DNA polymerase (Life Technologies) with M13F primer with fluorescence tag (6-FAM), amplicon-specific forward primer with M13 forward tail (5'-TGTAAACGACGGCCAGT-3') and 5'PIG-tailed (5'-GTGTCTT-3') amplicon-specific reverse primer for genotyping to identify alleles that contain a large deletion on the seed sequence of mir-204 ([@bib55]). An ABI 3730 Genetic Analyzer Avant (Thermofisher) was used to analyze the PCR products. All oligos used for genome editing are listed ([Supplementary file 2c](#supp2){ref-type="supplementary-material"}).

Cell culture and transfection {#s4-6}
-----------------------------

HMVEC-dLy (Lonza), HUVEC (GIBCO), and HEK293 (ATCC) were purchased and no evidence of *Mycoplasma* contamination was found. HMVEC-dLy cells (Lonza) were cultured in EGM-2 MV BulletKit (Lonza, CC-3202) that contains hEGF, hydrocortisone, GA-1000, FBS, VEGF, hFGF-B, R^3^-IGF-1, and ascorbic acid. HUVECs (Lonza) were cultured in bovine hypothalamus extract, 0.01% Heparin and 20% FBS in M199 base media (Gibco) on 1 mg/mL gelatin-coated tissue culture flasks. HEK293 cells were cultured in Advanced DMEM supplemented with 10% FBS and antibiotics. Transfection was performed using Lipofectamine 2000 (Invitrogen).

RNA isolation, small RNA-seq, and TaqMan PCR {#s4-7}
--------------------------------------------

RNA isolation was performed using the mirVana kit (Life Technoloiges). A NanoDrop ND-100 spectrophotometer (Nanodrop Technology Inc), Qubit 2.0 fluorometer (Life Technologies Inc) and Agilent 2100 bioanalyzer (Aglient) were used to analyze RNA quantity and quality. Small RNA sequencing was performed by ACGT, Inc. Three biological samples were subjected to analysis. Briefly, libraries were prepared using the Illumina TruSeq Small RNA Sample Preparation Kit, then sequenced on a NextSeq 500 Illumina instrument, generating 50 bp single end reads. Data was analyzed using PartekFlow analysis software (Partek, Inc). The sequence reads were trimmed to remove the following adapters: GTTCAGAGTTCTACAGTCCGACGATC (from the 5' end) and TGGAATTCTCGGGTGCCAAGG (from the 3' end). Then, the bases at the end of the sequences with quality less than 20 were removed. The remaining sequences were aligned to the human genome browser (hg38) and miRbase mature microRNA version 22 using Bowtie. The data was filtered for the counts smaller than 10 in 50% of samples, and used CPM (counts per million) for normalization. Differential expression was analyzed by Partek GSA algorithm. All supplies for TaqMan microRNA/gene assays were purchased from Life Technologies, and qPCR was performed using a CFX96 (BioRad). The mature microRNA sequences of all three zebrafish mir-204s are identical and could therefore be detected using a common mir-204 TaqMan assay. 18S rRNA (for human cells) and ef1a (for zebrafish cells) were used for internal controls for mRNAs, and U6 snRNA or mir-126 was used as an internal control for microRNAs.

Luciferase reporter assay {#s4-8}
-------------------------

The human NFATC1 3'UTR was PCR amplified from cDNA generated from human LEC RNA, and the zebrafish nfatc1 3'UTR from zebrafish embryo RNA. 3'UTR sequences were cloned downstream from the *renilla* luciferase gene using the XhoI and NotI sites in the psiCHECK-2 vector (Promega, Madison, WI). This vector also contains a *firefly* luciferase gene driven by an independent protomer, which serves an internal control for the assay. Mutations in the miR-204 binding sites were generated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and the mutated sequences were confirmed by DNA sequencing. All the primers used for generating luciferase constructs are listed ([Supplementary file 2a](#supp2){ref-type="supplementary-material"}). HEK293 cells transfected with luciferase reporters and microRNA mimics were harvested after 24 hr. A dual luciferase reporter assay system was used to determine luciferase levels (Promega, Madison, WI).

Imaging methods {#s4-9}
---------------

Embryos were anesthetized using 1x tricaine and mounted in 0.8--1.5% low melting point agarose dissolved in embryos media and mounted on a depression slide ([@bib22]). Time-lapse imaging was performed \~20 hr with image stacks acquired every 8 min. Confocal fluorescence imaging was performed with a Nikon Yokogawa CSU-W1 spinning disk confocal microscope. The images were analyzed using ImageJ ([@bib47]), Imaris 7.4 (Bitplane), Adobe Photoshop (Adobe), and NIS-Elements (Nikon) software.

Statistical analysis {#s4-10}
--------------------

Statistical significance was determined by using Student's t-test as indicated in the corresponding figure legends. At least three biological replicates per condition were used for quantitation. A biological replicate is defined as individual embryos or an independent culture of cells. The number of replicates are indicated in the figures or the legends. All quantitative data was analyzed used GraphPad Prism and Student's t-test.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"MicroRNA-mediated control of developmental lymphangiogenesis\" for peer review at *eLife*. Your article is being evaluated by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Marianne Bronner as the Senior Editor.

In the light of the comments made by the reviewers, we feel that significant revisions will be necessary before your manuscript can be published in *eLife*.

The comments of all three reviewers are in good agreement. While the reviewers found this work to be of some interest, they raised concerns about the strength of the conclusions that can be drawn at this stage and the appropriateness of the technical approach. The authors would be required to carefully address all comments point-by-point in a data-driven manner or with further analyses. Specifically, more expression analyses and better genetic evidence are required. Given that the authors intend to propose a link between miR-204 and Nfatc1, a more definite mechanism study that is supported by additional experiments is required. A stable Nfatc1 mutant instead of a morphant or CsA treatment would be a key control that is also essential. Double-knockout of mir-204-2 and mir-204-3 is also required to demonstrate the indispensable roles of mir-204. Please ensure your plan addresses these concerns and, if necessary, please provide the reasons for not implementing the suggested changes.

*Reviewer \#1:*

The post-transcriptional mechanisms in lymphatic vessel formation and patterning are barely understood. This is because it is still challenging to analyze phenotypes and investigate molecular mechanisms in miRNA-deficient model organisms. In this study, the authors successfully uncovered lymphatic-enriched miRNAs by small RNA sequencing analysis. In addition, they found interesting lymphatic phenotypes in the miR-204-deficient zebrafish and unveiled a target transcriptional factor regulated by miR-204, NFATC1. With this data and their pipeline for validating the functionality of lymphatic-enriched miRNAs, this study is expected to contribute to follow-up studies to determine post-transcriptional mechanisms in lymphatic vessel formation.

However, the role of miR-204 in lymphatic vessel formation is not yet conclusive and requires further clarification and investigation. It is still uncertain whether miR-204/NFATC1 interaction contributes to lymphatic vessel formation or patterning. Furthermore, how the expression of miR-204 is regulated during lymphatic vessel development needs to be investigated.

1\) In Figure 1, how is the expression of miR-204 being regulated during lymphatic vessel development? Is miR-204 always highly expressed in developing lymphatic endothelial cells (i.e. zebrafish lymphatic endothelial cells at 5dpf) and mature lymphatic endothelial cells (i.e. HMVEC-dLy), or is it dynamically regulated in a time-dependent manner?

2\) In Figure 2C, what is the authors\' opinion on the cause of different phenotypes depending on the dose of morpholinos?

3\) It is still uncertain whether miR-204/NFATC1 molecular pathway contributes to lymphatic vessel formation or patterning. In Figure 2E-N, Figure 3 and Figure 4, authors showed that miR-204 contributes to lymphatic vessel formation by loss-of and gain-of-function experiments. On the other hand, in Figure 6, nfatc1 seems to be required for lymphatic vessel patterning, not lymphatic vessel formation. According to the references the authors provided (Norrmen et al., 2009, Kulkarni et al., 2009), nfatc1 in mice also plays roles in lymphatic vessel patterning, not lymphatic vessel formation. Overall, miR-204 seems to work not only with nfatc1 signaling pathway but also with other signaling pathways, especially in lymphatic vessel formation. The authors need to clarify this issue.

4\) In line with comment 3, in Figure 7, it is unclear how deficient \'lymphatic vessel formation\' by Pan-204 MO could be rescued by \'lymphatic enlargement\' induced by nfatc1 MO. Careful analysis is required.

*Reviewer \#2:*

Jung et al. identify miR-204 as highly expressed in cultured human LECs and in sorted populations of early developing LECs from the zebrafish. They go on to show that morpholino knockdown of the 3 different mir-204 transcripts (from 3 genes) can lead to a loss of lymphatic vessel development. Importantly, they generate a miR-204-1 mutant animal and show that some combinations of MOs injected into this mutant can lead to a phenotype specific to the mutant embryos. They go onto identify NFATC1 as a possible target of miR-204 and to suggest a mechanism whereby miR-204 functions to suppress NFATC1 expression and that NFATC1 is itself a negative regulator of lymphatic vessel size.

While the work is interesting and may offer up an unexpected new mechanism controlling lymphatic development. There are several questions remaining and loose ends that should be better completed to give more confidence in the central findings.

Major issues:

1\) miR-204 has been previously analysed in zebrafish and medaka and prominent expression reported in epithelia and the eye (retinal epithelia and lens). In these previous studies using LNA in situ hybridisation (Conte et al., 2010, Weinholds et al., 2005) there was no indication of vascular expression. The authors should provide evidence with a similar approach that miR-204 is expressed autonomously in intact embryos in the vasculature.

It is possible that the function of miR-204 may be non-autonomous in the current report and so at least showing in situ expression in tissues would improve confidence in the current data.

2\) The paper relies heavily on the use of MO knockdown which has become increasingly controversial in the zebrafish field. Having one mutant in miR-204-1 is welcome and does improve confidence. However, while this reviewer appreciates that asking for triple mutants is perhaps too much, there are some inconsistencies that are concerning. For example, MO1 + MO2 gives a loss of lymphatics but the mutant for 204-1 + MO2 does not. How can this be explained? Can additional evidence such as transient CRISPR for 204-2 or -3 in the miR-204-1 mutant or similar be provided to further improve confidence in these data with multiple overlapping approaches?

3). The analysis of phenotype is very superficial. Is specification of LECs impacted? Is LEC cell number at the parachordal line or thoracic duct quantitatively reduced? Is there signalling induced downstream of Vegf-c and Vegf-r3? Eg. pERK such as shown in Shin et al., 2016.

Along the same lines the phenotypic analysis of the overexpression transgenic for miR-204 and in the NFATC1 vessels should include cell number counts for LECs. This is important as scoring vessel area in 2D images could indicate increased LECs or increased vessel dilation (more luminal content). The NFATC1 mutant could be a fluid imbalance phenotype and unrelated to the miR-204 overexpression phenotype or miR-204 mutant/MO phenotype without further more careful phenotypic analysis.

4). The overexpression of miR-204 gives premature thoracic duct development but the embryo shown looks older than the control (increased distance between DA and PCV). The experiment is also under-controlled. Please provide analysis of markers of other tissues to control for staging differences (eg. rag1 expression in thymus is a useful marker that comes on progressively from around 2.5 dpf). Please also show how much the endothelial levels of miR-204 are increased in the transgenic -- miRNA\'s are typically highly expressed and Figure 1 suggests very high levels of miR-204 already in LECs, so why would one expect such a phenotype upon over-expression?

5\) Is NFATC1 expressed in LECs and the PCV in zebrafish by ISH? Is the expression increased upon progressive loss of miR-204 in the mutants and MO scenarios?

6\) The analysis of NFATC1 phenotype to correlate with miR-204 phenotypes relies exclusively upon MO knockdown and the use of CsA, an inhibitor commonly considered to have broad impact on embryos. Unlike the miR targeting, where it is difficult to expect generation of triple mutants, analysis of a stable NFATC1 mutant does not seem an unreasonable thing to ask for. It is likely that a mutant may be available already. The authors should provide more confidence in their increased lymphangiogenesis phenotype upon NFATC1 loss of function by including the analysis of a mutant strain. Alternatively (or additionally), they could consider targeting the miR-binding site in the 3\'UTR to definitively demonstrate their mechanism.

7\) The honing in on NFATC1 as a target came without explanation of how many miR-204 targets are predicted in vasculature. Providing additional bioinformatic prediction would improve the study. How many LEC transcripts have predicted miR-204 target sites? Is this statistically enriched over other cell types? How does NFATC1 rank as a predicted target taking into account the number of predicted sites, homology etc?

*Reviewer \#3:*

Jung HM, et al. report a potential mir-204-dependent regulation of lymphatic vessel (LV) growth through NFATC1. First, the authors identified mir-204 as a lymphatic endothelial cells (LECs)-enriched miRNA compared to vascular endothelial cells (VECs). There were three mir-204 in zebrafish: mir-204-1, (in the intron of 5 of trpm3), mir-204-2 (in the intron of trp1ma), and mir-204-3 (in the intron of 4 of trp1mb). They demonstrated the requirement of miR-204 in lymphatic vessel development by using mir-204-1 mutants treated with both mir-204-2 and -3 morpholinos and mir-204-1, -2, -3 morphants (total morphants). Furthermore, NFATC1 was reported to be a potential target of mir-204, because the transcription of nfatc1 was increased in the mir-204 total morphants and was decreased in the reporter assay using mir-204. They also demonstrated the potential involvement of NFATC1 in LV growth by showing nfatc1 morphants and a calcineurin inhibitor, cyclosporin A. The hierarchical gene regulation between mir-204 and nfatc1 for LV development was validated by the restoration of LV impairment found in mir-204 morphants in the mir-204 morphants treated with nfatc1 morpholinos.

This study is well organized and written in a logical manner. There are still several points that should be addressed to support their claim.

1\) It is unclear why the authors need to compare zebrafish and human? The conservation of mir-204-dependent regulation of NFATC1 among zebrafish and human might be interesting: however, the authors could identify mir-201 using mir-RNAs from the *Tg(mrc1a:eGFP)^y251^* and *Tg(kdrl:mCherry)^y171^* as shown in Figure 1F. Because the importance of mir-204 in zebrafish is focused in this study, the list of mir using the mir from the FACS-sorted cells should be used as an initial material. The authors might do this experiment easily using their Tg fish.

The result shown in Figure 1A, B, C should become Figure supplement.

2\) In addition to \#1, time course of mir expression should be demonstrated at least at two points when the secondary sprout starts and when thoracic duct formation is completed. The authors merely showed the expression of mir-204 in the zebrafish embryos at 5 dpf.

3\) The requirement of mir-204 is partially proven in this study. As the authors explained in Figure 3, they need to do the similar experiments using mir-204-^2\ -/-^ + MO1, 3 and mir-204-3 ^-/-^ + MO1, 2. It is not so difficult to complete these experiments by establishing mir-204-2 mutant and mir-204-3 mutant. They describe the detail of mir-204-2 and mir-204-3 in Figure 2---figure supplement 1.

4\) The potential target of mir-204 is not described well. The authors described this in the Discussion. The reason why Nfatc1 was picked up is not clearly described in the present manuscript. The authors examined Nfatc1 following the prediction of RNA22 database. There are several microRNA target databases beside RNA22. Thus, targets expected in other database should be examined as a negative control.

5\) To more precisely show the hierarchical regulation of mir-204 and nfatc1, the authors can examine the expression of nfatc1 using FACS-sorted LECs of *Tg8mrc1a:eGFP)^y251^* total morphants (mir-204-1, -2,-3 morphants).

6\) It is unclear whether secondary sprout is affected in mir-204 deficient embryos. Although there are no parachordal lines in the scheme of Figure 7L, there is no evidence of impairment of secondary sprout followed by parachordal line development in the present study. Although the authors focused on thoracic duct formation, prior to this, secondary sprout and parachordal lines could be analyzed. No description in Figure 3.

7\) The authors mentioned \"lymphatic specification\" in Discussion. They can interpret their data when carefully examine the effect of depletion of mir-204 and nfatc1 on secondary sprout and subsequent parachordal lines.

10.7554/eLife.46007.033

Author response

> The comments of all three reviewers are in good agreement. While the reviewers found this work to be of some interest, they raised concerns about the strength of the conclusions that can be drawn at this stage and the appropriateness of the technical approach. The authors would be required to carefully address all comments point-by-point in a data-driven manner or with further analyses. Specifically, more expression analyses and better genetic evidence are required. Given that the authors intend to propose a link between miR-204 and Nfatc1, a more definite mechanism study that is supported by additional experiments is required. A stable Nfatc1 mutant instead of a morphant or CsA treatment would be a key control that is also essential. Double-knockout of mir-204-2 and mir-204-3 is also required to demonstrate the indispensable roles of mir-204. Please ensure your plan addresses these concerns and, if necessary, please provide the reasons for not implementing the suggested changes.

In response to the reviews of our original submission we agreed on an "Action Plan" for carrying out a large number of new experiments for our revision. We completed all of the proposed experiments, yielding important new data that has further strengthened our conclusions:

Knock down miR-204-2 in the miR-204-1 mutant

As promised, we injected miR-204-2 or miR-204-3 morpholinos into miR-204-1^-/-^ mutants (Figure 3) and obtained essentially identical results to the comparable experiments we performed using a morpholino targeting miR-204-1 instead of a miR-204-1^-/-^ genetic mutant (Figure 2---figure supplement 2). That is, combined targeting of miR-204-1 and miR-204-2 gives a lymphatic phenotype, but combined targeting of miR-204-1 and miR-204-3 does not, regardless of whether a mutant or a morpholino is used to target miR204-1. The symmetry of these results again supports a specific role for miR-204 in lymphatic development. Perform miR-204 transplant/transgene mosaic knockdown and "rescue" experiments to validate and examine their endothelial- cell specific phenotypes

As promised, we carried out experiments demonstrating that endothelial-specific expression of miR-2041 "rescues" the lymphatic defects in miR-204-1^-/-^ mutants injected with a morpholino blocking maturation of miR-204-2 (Figure 4E-K). These new data strongly confirm that the lymphatic phenotype of miR-204deficient animals is due to loss of endothelial miR-204 function, and that miR-204 is required autonomously in the endothelium for generating lymphatics. We also now show that endothelial-specific mosaic expression of miR-204-1 in wild-type animals causes precocious thoracic duct development (Figure 4A-D), further confirming that this phenotype can manifest itself in an endothelial-autonomous manner in otherwise normally developing animals.

Examine early stages of lymphatic development in miR-204-deficient animals

As further promised, we carried out time-lapse imaging of "secondary sprouts" (early pre-lymphatic sprouts that emerge from the cardinal vein) to examine whether initial specification and sprouting is defective, or later patterning and growth. Our results show that secondary sprouts in miR-204 deficient animals emerge and grow up to the level of the horizontal myoseptum normally. However, while secondary sprouts in control animals stop at the myoseptum, turn laterally, and form the parachordal lines (Figure 2C), secondary sprouts in miR-204 deficient animals fail to stop at the level of the myoseptum but continue growing dorsally, in many cases eventually contributing to the venous circulation (Figure 2D, Figure 2---video 1, and Figure 3---figure supplement 1). We would note that we have not observed this unusual and unique phenotype in any of our previous studies where we functionally manipulated genes important for lymphatic development in the zebrafish.

Analyze NFATC mutants

As also promised, we generated and analyzed CRISPR mutants in *nfatc1*, including a frameshift mutation creating a premature stop codon (Figure 6F). Our new *nfatc1*^△^*^8/^*^△^*^8^*mutants exhibit the same enlarged thoracic duct phenotype (Figure 6G-K) observed in animals injected with nfatc1 splice-blocking morpholinos (Figure 6A-E). Furthermore, we have also analyzed the phenotypes of animals injected with a separate nfatc1 translation-blocking (ATG) morpholino, and this second morpholino also gives the same enlarged thoracic duct phenotype observed in nfatc1 splice-blocking morphants (Figure 6---figure supplement 1A-E). Thus, the new nfatc1 mutant and nfatc1 ATG morphants phenocopy the lymphatic phenotypes we noted previously in animals injected with splice blocking morpholino (Figure 6) or treated with cyclosporine A (Figure 6---figure supplement 1F-J).

Explain our focus on NFATC as a key miR-204 target

As also promised, we have added an explanation to our Results section detailing the reasons for our focus on NFATC as a key miR-204 target. As we write:

"Based on our observation that miR-204 plays role during lymphatic development, we began our search for potential important target genes by (i) starting with a list of human genes previously implicated in lymphatic development, then (ii) bioinformatically identifying which genes in this set had potential miR204 target sites using TargetScan, and then (iii) bioinformatically identifying which of these genes also had corresponding zebrafish orthologs with potential miR-204 target sites (in order to ensure that we were looking at key, conserved targets that we could functionally study in both human cell culture and in zebrafish (Supplementary file 1). The Nuclear Factor of Activated T Cells 1 (NFATC1) gene immediately came to our attention as a strong candidate."

As we noted previously, we recognize of course that microRNAs can have hundreds of potential targets, and our original goal in testing nfatc1 had been mainly to validate that miR-204 did indeed target and regulate at least one gene important for lymphatic development. It was a bit of a surprise to us that nfatc1 knockdown (or mutants) gave us a nice lymphatic phenotype, and a big (but very gratifying!) surprise that we could so effectively rescue miR-204 deficiency by knocking down nfatc1.

Analyze mir-204 mutants

As promised, we generated and analyzed miR-204 triple mutants (Figure 3---figure supplement 2). Generating triple mutants was very challenging given the extremely limited genomic targets available for disrupting the microRNAs, but we succeeded in generating animals with CRISPR mutants deleting all or part of the seed sequences at the miR-204-1, miR-204-2, and miR-204-3 loci (Figure 3---figure supplement 2A). Homozygous triple mutant animals lack detectable expression of qPCR-amplifiable mature miR-204 (Figure 3---figure supplement 2C), but they do not exhibit a quantifiably significant loss of thoracic duct formation (Figure 3---figure supplement 2D). The latter result was unexpected, but for reasons detailed below involving a large amount of other newly generated data in this revision, our findings strongly suggest that miR-204 function is indeed regulating lymphatic development and that an unknown compensatory mechanism limits the phenotype in our triple mutants.

Newly generated data in this revision supporting a lymphatic role for miR-204 include:

i\) Combined loss of miR-204-1 and miR-204-2 (but not miR-204-1 and miR-204-3) results in identical lymphatic phenotypes regardless of whether miR-204-1 is being knocked down using a morpholino (Figure 2---figure supplement 2) or eliminated using a genetic mutant (Figure 3). Our new findings using the miR204-1 mutant injected with either miR-204-2 or miR-204-3 morpholinos (Figure 3) replicate and fully confirm our previous morpholino-only results (Figure 2---figure supplement 2) showing that miR-204-3 is dispensable.

ii\) The loss-of-lymphatic phenotype of miR-204-1^-/-^ mutants injected with miR-204-2 morpholinos is "rescued" by endothelial-specific expression of miR-204-1 (Figure 4E-K). These new data strongly confirm that the lymphatic phenotype of miR-204-deficient animals is due to loss of endothelial miR-204 function, and that miR-204 is required autonomously in the endothelium for generating lymphatics. These data further support our results indicating that the phenotype is not due to nonspecific morpholino effects.

iii\) miR-204-deficient animals do not have a defect in either the formation or the initial growth of the secondary sprouts derived from the cardinal vein. Secondary sprouts in these animals fail to halt at the horizontal myoseptum and form the parachordal line as they do in control animals (Figure 2C), but instead continue to grow dorsally and in many cases contribute to veins (Figure 2D; Figure 2---video 1; Figure 3---figure supplement 1). The unusual phenotype of abnormal ongoing dorsal growth of secondary sprouts, together with the otherwise normal overall development of miR-204 deficient animals, suggests that failure to form the parachordal and subsequently thoracic duct is not a result of nonspecific developmental problems in these animals. The abnormal secondary sprout growth and patterning phenotype we have now demonstrated in miR-204 deficient animals is a unique phenotype that we have not observed in the many other lymphatic-defective mutants and morphants we have examined over the years.

We would note again that knockdown with the single pan-204 morpholino targeting all mature miR-204 sequences or knockdown with a combination of two distinct morpholinos blocking maturation of miR204-1 and miR-204-2 (but not miR-204-3) gives the same very unique lymphatic phenotype described in iii) above.

There is precedent in the literature for zebrafish microRNA mutants failing to exhibit the full phenotypes noted in microRNA knockdown studies. Suppression of the evolutionarily conserved endothelial-enriched microRNA mir-126 causes blood vessel defects in mir-126 morpholino-injected animals (Fish et al., 2008) Zou et al., 2011), although lower dose morpholino injections cause mainly lymphatic defects with relatively minor effects on blood vessels (Chen et al., 2016). Interestingly, mir-126 mutant zebrafish also lack the vascular phenotype described in the previous morpholino studies and display only the defects in lymphatic vessel development seen with partial knockdowns (Kontarakis et al., 2018), suggesting some compensation may be taking place in miR-126 mutants.

Reviewer \#1:

> \[...\] However, the role of miR-204 in lymphatic vessel formation is not yet conclusive and requires further clarification and investigation. It is still uncertain whether miR-204/NFATC1 interaction contributes to lymphatic vessel formation or patterning. Furthermore, how the expression of miR-204 is regulated during lymphatic vessel development needs to be investigated.
>
> 1\) In Figure 1, how is the expression of miR-204 being regulated during lymphatic vessel development? Is miR-204 always highly expressed in developing lymphatic endothelial cells (i.e. zebrafish lymphatic endothelial cells at 5dpf) and mature lymphatic endothelial cells (i.e. HMVEC-dLy), or is it dynamically regulated in a time-dependent manner?

As noted by the reviewer, we observed high levels of miR-204 expression in both developing zebrafish lymphatics (Figure 1F) and in mature human endothelial cells (Figure 1C), suggesting that miR-204 is maintained at high levels from initial lymphatic development. The mechanisms responsible for establishing the lymphatic vs. blood endothelial expression of miR-204 would certainly be a topic of great interest for future studies.

> 2\) In Figure 2C, what is the authors\' opinion on the cause of different phenotypes depending on the dose of morpholinos?

To avoid potential off-target effects from morpholino injections we conducted careful dose response curves to select doses that do not generate obvious gross morphological or other abnormalities. At the 0.5 ng Pan-204 MO dose we detect no noticeable non-vascular abnormalities, while at the higher 0.75 ng dose we see additional effects including smaller eyes, pericardial edema, and craniofacial deformation. While these phenotypes may be associated with reduced miR-204 function, we decided to use the 0.5 ng to avoid potential secondary effects on lymphatics caused by these other abnormalities. This panel was moved to Figure 2---figure supplement 1C.

> 3\) It is still uncertain whether miR-204/NFATC1 molecular pathway contributes to lymphatic vessel formation or patterning. In Figure 2E-N, Figure 3 and Figure 4, authors showed that miR-204 contributes to lymphatic vessel formation by loss-of and gain-of-function experiments. On the other hand, in Figure 6, nfatc1 seems to be required for lymphatic vessel patterning, not lymphatic vessel formation. According to the references the authors provided (Norrmen et al., 2009, Kulkarni et al., 2009), nfatc1 in mice also plays roles in lymphatic vessel patterning, not lymphatic vessel formation. Overall, miR-204 seems to work not only with nfatc1 signaling pathway but also with other signaling pathways, especially in lymphatic vessel formation. The authors need to clarify this issue.

In response to this and other comments we carried out additional experiments to provide more information on how suppressing the miR-204 pathway is interfering with proper lymphatic vascular development. As noted above, we carried out time-lapse imaging of "secondary sprouts," early prelymphatic sprouts that emerge from the cardinal vein. Our results show that secondary sprouts initially form normally in miR-204 deficient animals and grow normally up to the level of the horizontal myoseptum. However, while secondary sprouts in control animals stop at the myoseptum, turn laterally, and form the parachordal lines (Figure 2C), secondary sprouts in miR-204 deficient animals fail to stop at the level of the myoseptum but continue growing dorsally, in many cases eventually contributing to the venous circulation (Figure 2D, Figure 2---video 1, and Figure 3---figure supplement 1). As also noted above, while nfatc1 axis is not the only gene downstream from miR204, knocking down nfatc1 in the mir-204-deficient animals successfully rescues the lymphatic phenotype. This result suggests that nfatc1 pathway is at least a major important downstream target.

> 4\) In line with comment 3, in Figure 7, it is unclear how deficient \'lymphatic vessel formation\' by Pan-204 MO could be rescued by \'lymphatic enlargement\' induced by nfatc1 MO. Careful analysis is required.

From our data it appears that increased levels of NFATC1 (in miR-204-deficient animals) lead to failure of secondary sprouts to form parachordals and subsequently lymphatics, while reduced NFATC1 leads to lymphatic enlargement. The relationship between these phenotypes is indeed unclear -- they may reflect differential engagement of the same or different downstream pathways. Clearly understanding the molecular pathways and cellular processes activated or suppressed by too little or too much NFATC1 will be a very interesting area for future research investigation, but this is beyond the scope of the present study, which already goes from an unbiased in vitro screen identifying lymphatic microRNAs, to identification of a functionally important microRNA, to the identification and initial functional study of a key target for this microRNA.

Reviewer \#2:

> \[...\] Major issues:
>
> 1\) miR-204 has been previously analysed in zebrafish and medaka and prominent expression reported in epithelia and the eye (retinal epithelia and lens). In these previous studies using LNA in situ hybridisation (Conte et al. 2010, Weinholds et al., 2005 paper) there was no indication of vascular expression. The authors should provide evidence with a similar approach that miR-204 is expressed autonomously in intact embryos in the vasculature.
>
> It is possible that the function of miR-204 may be non-autonomous in the current report and so at least showing in situ expression in tissues would improve confidence in the current data.

In response to this and other reviewer comments, we have now carried out additional experiments that show that endothelial cell-autonomous expression of mir-204 "rescues" the lymphatic defects in miR-204-1^-/-^ mutants injected with a morpholino blocking maturation of miR-204-2 (Figure 4E-K), and causes precocious thoracic duct development in wild type animals (Figure 4A-D). These new data strongly confirm that miR-204 function is required autonomously in the endothelium for lymphatic development.

We attempted LNA in situ for miR-204 but the sensitivity in our experiments was not sufficient to detect vascular expression, unlike the eye where miR-204 is more highly expressed. LNA in situ hybridization is an excellent method for detecting highly abundant transcripts, but very challenging and not always successful for relatively low copy number transcripts, particularly when dealing with small RNAs where options for design of the probe are extremely limited. However, our qPCR on the FACS-sorted arterial, venous, and lymphatic endothelial cells from transgenic zebrafish shows that miR-204 is highly enriched in the lymphatic endothelial cell population (Figure 1F).

> 2\) The paper relies heavily on the use of MO knockdown which has become increasingly controversial in the zebrafish field. Having one mutant in miR-204-1 is welcome and does improve confidence. However, while this reviewer appreciates that asking for triple mutants is perhaps too much, there are some inconsistencies that are concerning. For example, MO1 + MO2 gives a loss of lymphatics but the mutant for 204-1 + MO2 does not. How can this be explained? Can additional evidence such as transient CRISPR for 204-2 or -3 in the miR-204-1 mutant or similar be provided to further improve confidence in these data with multiple overlapping approaches?

We have carried out a variety of additional experiments for this revision to further substantiate the important role of miR-204 in lymphatic development (as also discussed in detail above), including showing that a mutant for 204-1 + MO2 gives the same loss of lymphatics phenotype as MO1 + MO2:

We now show that combined targeting of miR-204-1 and miR-204-2 gives a lymphatic phenotype but combined targeting of miR-204-1 and miR-204-3 does not, regardless of whether miR-204-1 is targeted using a mutant or a morpholino (Figure 2---figure supplement 2, Figure 3). Although in our original submission we targeted both miR-204-2 and miR-204-3 together with morpholinos in the miR204-1 mutant, we had not actually previously done the experiment noted above by the reviewer of targeting only miR-204-2 with a morpholino in the miR-204-1 mutant.

We now show that transgenic endothelial-specific expression of miR-204 can both rescue the lymphatic defect in mir-204 deficient animals (Figure 4E-K) and cause precocious thoracic duct development in wild type animals (Figure 4A-D).

We now show that miR-204 deficient animals have a striking and unusual phenotype of misdirected secondary sprouts that fail to stop at the horizontal myoseptum to form the pre-lymphatic parachordal line (Figure 2C), but instead continue to grow dorsally and in many cases contribute to veins (Figure 2D; Figure 2---video 1; Figure 3---figure supplement 1).

> 3). The analysis of phenotype is very superficial. Is specification of LECs impacted? Is LEC cell number at the parachordal line or thoracic duct quantitatively reduced? Is there signalling induced downstream of Vegf-c and Vegf-r3? Eg. pERK such as shown in Shin et al., 2016.

In response to these and other comments, we have carried out a more detailed analysis of the miR204 deficient phenotype, showing that secondary sprouts form and grow to the horizontal myoseptum as in wild type animals, but instead of forming the pre-lymphatic parachordal line at the horizontal myoseptum they continue to grow dorsally and at least some contribute to veins (Figure 2C, D; Figure 2---video 1; Figure 3---figure supplement 1). While a more detailed molecular characterization of the role of miR-204 would be of interest for future studies, we believe it is beyond the scope of the present study, which already goes from an unbiased in vitro screen identifying lymphatic microRNAs to identification of a functionally important microRNA, to the identification and functional validation of a key target for this microRNA.

> Along the same lines the phenotypic analysis of the overexpression transgenic for miR-204 and in the NFATC1 vessels should include cell number counts for LECs. This is important as scoring vessel area in 2D images could indicate increased LECs or increased vessel dilation (more luminal content). The NFATC1 mutant could be a fluid imbalance phenotype and unrelated to the miR-204 overexpression phenotype or miR-204 mutant/MO phenotype without further more careful phenotypic analysis.

We have not observed an increase in the number of LEC in the thoracic ducts of nfatc1-deficient animals using counts of endothelial cell nuclei. The reason for the lymphatic hyperplasia phenotype (also noted in mice) remains unclear at this point, but we have not observed defects in flow through the thoracic duct in preliminary lymphatic drainage experiments (data not shown).

> 4). The overexpression of miR-204 gives premature thoracic duct development but the embryo shown looks older than the control (increased distance between DA and PCV). The experiment is also under-controlled. Please provide analysis of markers of other tissues to control for staging differences (eg. rag1 expression in thymus is a useful marker that comes on progressively from around 2.5 dpf). Please also show how much the endothelial levels of miR-204 are increased in the transgenic -- miRNA\'s are typically highly expressed and Figure one suggests very high levels of miR-204 already in LECs, so why would one expect such a phenotype upon over-expression?

We carefully repeated the miR-204 germline transgenic overexpression experiment together with measurement of the distance between DA and PCV, and observed precocious thoracic duct formation without change in the DA/PCV distance (Figure 4---figure supplement 1). We measured an approximately 2-fold increase in miR-204 levels in these germline transgenic animals (Figure 4---figure supplement 1E).

To address this question experimentally in another and perhaps more direct way, we also showed that mosaic endothelial-specific expression of miR-204 in otherwise wild type, normally-developing animals also leads to precocious thoracic duct formation (Figure 4A-D).

> 5\) Is NFATC1 expressed in LECs and the PCV in zebrafish by ISH? Is the expression increased upon progressive loss of miR-204 in the mutants and MO scenarios?

Previous reports have noted nfatc1 expression in the endothelium in various species including zebrafish (e.g. Coxam et al., Cell Reports 7:623, 2014), and we and others have shown that NFATC1 is differentially expressed at higher levels in LEC. We show that miR-204 mimic decreases and miR-204 inhibitor increases NFATC1 expression in HUVEC in vitro(Figure 5C) and that miR-204 deficient zebrafish have increasedin vivonfatc1 expression (Figure 5F), clearly demonstrate that NFATC1 is a target of miR-204 regulation.

> 6\) The analysis of NFATC1 phenotype to correlate with miR-204 phenotypes relies exclusively upon MO knockdown and the use of CsA, an inhibitor commonly considered to have broad impact on embryos. Unlike the miR targeting, where it is difficult to expect generation of triple mutants, analysis of a stable NFATC1 mutant does not seem an unreasonable thing to ask for. It is likely that a mutant may be available already. The authors should provide more confidence in their increased lymphangiogenesis phenotype upon NFATC1 loss of function by including the analysis of a mutant strain. Alternatively (or additionally), they could consider targeting the miR-binding site in the 3\'UTR to definitively demonstrate their mechanism.

In response to this and other reviewer comments, we now demonstrate that [two]{.ul} separate nfatc1 morpholinos, cyclosporine treatment targeting NFAT signaling, [and]{.ul} a newly generated nfatc1 mutant all result in the same lymphatic enlargement phenotype (Figure 6, Figure 6---figure supplement 1).

> 7\) The honing in on NFATC1 as a target came without explanation of how many miR-204 targets are predicted in vasculature. Providing additional bioinformatic prediction would improve the study. How many LEC transcripts have predicted miR-204 target sites? Is this statistically enriched over other cell types? How does NFATC1 rank as a predicted target taking into account the number of predicted sites, homology etc?

We provide a detailed response to this comment in the "Explain our focus on NFATC as a key miR-204 target" section (under "New experimental data provided for revision") above. As we noted previously, we recognize of course that microRNAs can have hundreds of potential targets, and our original goal in testing nfatc1 had been just to validate that miR-204 did indeed target and regulate at least one gene known to be important for lymphatic development. It was a bit of a surprise to us that nfatc1 knockdown or mutants gave us a nice lymphatic phenotype, and a big surprise that we could so effectively rescue miR-204 deficiency by knocking down nfatc1.

Reviewer \#3:

> \[...\] This study is well organized and written in a logical manner. There are still several points that should be addressed to support their claim.
>
> 1\) It is unclear why the authors need to compare zebrafish and human? The conservation of mir-204-dependent regulation of NFATC1 among zebrafish and human might be interesting: however, the authors could identify mir-201 using mir-RNAs from the Tg(mrc1a:eGFP)^y251^ and Tg(kdrl:mCherry)^y171^ as shown in Figure 1F. Because the importance of mir-204 in zebrafish is focused in this study, the list of mir using the mir from the FACS-sorted cells should be used as an initial material. The authors might do this experiment easily using their Tg fish.
>
> The result shown in Figure 1A, B, C should become Figure supplement.

We used both human and zebrafish models for several reasons, but mainly (i) to ensure that we were looking at important evolutionarily conserved microRNA regulators of lymphatic development, and (ii) to provide complementary in vitroand in vivo models enabling a full range of experimental paradigms to be employed. We began by carrying out the small RNAseq using human cells mainly for technical reasons (eg, obtaining ample starting material for preparation of highly representative and replicated sequencing libraries), but also to permit comparison to previous screens carried out using human cells.

> 2\) In addition to \#1, time course of mir expression should be demonstrated at least at two points when the secondary sprout starts and when thoracic duct formation is completed. The authors merely showed the expression of mir-204 in the zebrafish embryos at 5 dpf.

It is not technically possible to obtain sorted lymphatic/lymphatic progenitor cells from our double transgenic animals at early stages when secondary sprouting begins -- there are extremely few lymphatic progenitor cells at this stage to begin with and these cells are not yet "single labeled" with only GFP, so they cannot be sorted out as a separate population.

> 3\) The requirement of mir-204 is partially proven in this study. As the authors explained in Figure 3, they need to do the similar experiments using mir-204-2 ^-/-^ + MO1, 3 and mir-204-3 ^-/-^ + MO1, 2. It is not so difficult to complete these experiments by establishing mir-204-2 mutant and mir-204-3 mutant. They describe the detail of mir-204-2 and mir-204-3 in Figure 2---figure supplement 1.

As noted in the "Analyze mir-204 mutants" section (under "New experimental data provided for revision") above, we have added a large amount of new data reinforcing our conclusion that miR-204 is required cell-autonomously for proper lymphatic development.

> 4\) The potential target of mir-204 is not described well. The authors described this in the Discussion. The reason why Nfatc1 was picked up is not clearly described in the present manuscript. The authors examined Nfatc1 following the prediction of RNA22 database. There are several microRNA target databases beside RNA22. Thus, targets expected in other database should be examined as a negative control.

Please see the "Explain our focus on NFATC as a key miR-204 target" section (under "New experimental data provided for revision") above, where we provide a more complete explanation of how and why we selected NFATC1 for further analysis. Again, our original intent was merely to demonstrate that miR-204 modulated a factor previously shown to be important for lymphatic development. The nfatc1 morphant/mutant phenotypes and especially the successful rescue of miR-204 deficient animals by inhibiting nfatc1 expression were welcome surprises!

> 5\) To more precisely show the hierarchical regulation of mir-204 and nfatc1, the authors can examine the expression of nfatc1 using FACS-sorted LECs of Tg8mrc1a:eGFP)^y251^ total morphants (mir-204-1, -2,-3 morphants).

We report that miR-204 deficient zebrafish have increasedin vivonfatc1 expression (Figure 5F). We also show that miR-204 mimic decreases and miR-204 inhibitor increases NFATC1 expression in HUVEC in vitro(Figure 5C). These results demonstrate that NFATC1 is a target of miR-204 regulation.

> 6\) It is unclear whether secondary sprout is affected in mir-204 deficient embryos. Although there are no parachordal lines in the scheme of Figure 7L, there is no evidence of impairment of secondary sprout followed by parachordal line development in the present study. Although the authors focused on thoracic duct formation, prior to this, secondary sprout and parachordal lines could be analyzed. No description in Figure 3.

In response to this and other comments from our reviewers, and as described in detail in the "Examine early stages of lymphatic development in miR-204-deficient animals" section (under "New experimental data provided for revision") above, we now include new time-lapse imaging data showing that secondary sprouts in miR-204 deficient animals emerge and grow to the level of the horizontal myoseptum as in normal animals but then fail to form the pre-lymphatic parachordal lines and instead continue to grow dorsally, in at least some cases contributing to veins (Figure 2C, D; Figure 2---video 1; and Figure 3---figure supplement 1).

> 7\) The authors mentioned \"lymphatic specification\" in Discussion. They can interpret their data when carefully examine the effect of depletion of mir-204 and nfatc1 on secondary sprout and subsequent parachordal lines.

Please see our comments in the response to point \#6 above, and in the "Examine early stages of lymphatic development in miR-204-deficient animals" section (under "New experimental data provided for revision"). Our new data shows that secondary sprouts form and grow normally to the myoseptum but are then misdirected and fail to contribute to the parachordal lines. In addition to the new data we have added new text to our manuscript discussing these findings.
